A Novel Immune-related Gene Prognostic Signature Combining Immune Cell Infiltration and Immune Checkpoint for Glioblastoma Patients

Overview

Journal Transl Cancer Res

Specialty Oncology

Date 2024 Dec 19

PMID 39697704

Authors

Xu Liu

Xiaomei Liu

Affiliations

Soon will be listed here.

Abstract

Background: Glioblastoma (GBM) is a highly lethal brain tumor with a complex tumor microenvironment (TME) and poor prognosis. This study aimed to develop and validate a novel immune-related prognostic model for GBM patients to enhance personalized prognosis prediction and develop effective therapeutic strategies.

Methods: RNA sequencing and clinical data for GBM patients were obtained from The Cancer Genome Atlas (TCGA) and the Gene Expression Omnibus (GEO) (GSE83300). Single-sample gene set enrichment analysis (ssGSEA) was performed using the gene set variation analysis (GSVA) package in R to classify the samples into high and low immune infiltration clusters based on 29 immune cell subtypes. Clustering validations included differential analysis of immune scores and comparison of human leukocyte antigen (HLA) family expression and immune cell subtypes. Kyoto Encyclopedia of Genes and Genomes (KEGG) pathway analysis and Gene Ontology (GO) analysis compared molecular mechanisms and cellular functions between clusters. Differentially expressed immune-related genes between the high and low immune infiltration clusters were screened out, and the prognostic immune-related genes (PIGs) were identified using univariate Cox regression. Co-expression analysis between PIGs and transcription factors (TFs) (Cistrome) was conducted, and a protein-protein interaction (PPI) network (STRING) was constructed. Least absolute shrinkage and selection operator (LASSO) regression constructed a prognostic model. Correlation analyses between PIGs, immune infiltrates, and GBM-related genes were performed. Tumor mutation burden (TMB) analysis and a nomogram incorporating age, gender, and risk score were developed for individualized prognosis prediction.

Results: A total of 312 differentially expressed immune-related genes were identified between high and low immune infiltration clusters. Of these, 28 genes were correlated with GBM prognosis. LASSO regression identified 10 genes (, and ) for the prognostic model. Patients were divided into high-risk and low-risk groups based on risk scores. Survival analysis showed significantly better overall survival (OS) for the low-risk group (P<0.05). The prognostic signature was validated as an independent prognostic factor. Correlation analyses demonstrated significant associations between the prognostic model, immune cell infiltrates, GBM-related genes, and immune checkpoint-related genes. A nomogram incorporating age, gender, and risk score was developed for personalized prognosis prediction.

Conclusions: In summary, our study provided a novel prognostic model based on ssGSEA for GBM patients and offered potential insights for understanding the tumor immune and molecular mechanisms of the disease.

References

Chen L, Flies D . Molecular mechanisms of T cell co-stimulation and co-inhibition. Nat Rev Immunol. 2013; 13(4):227-42. PMC: 3786574. DOI: 10.1038/nri3405. View

Zhang H, Wang Y, Zhao Y, Liu T, Wang Z, Zhang N . PTX3 mediates the infiltration, migration, and inflammation-resolving-polarization of macrophages in glioblastoma. CNS Neurosci Ther. 2022; 28(11):1748-1766. PMC: 9532932. DOI: 10.1111/cns.13913. View

Ciciola P, Cascetta P, Bianco C, Formisano L, Bianco R . Combining Immune Checkpoint Inhibitors with Anti-Angiogenic Agents. J Clin Med. 2020; 9(3). PMC: 7141336. DOI: 10.3390/jcm9030675. View

Park J, Lee H . The Role of Hypoxia in Brain Tumor Immune Responses. Brain Tumor Res Treat. 2023; 11(1):39-46. PMC: 9911710. DOI: 10.14791/btrt.2022.0043. View

Yuan F, Cai X, Zhu J, Yuan L, Wang Y, Tang C . A Novel Immune Classification for Predicting Immunotherapy Responsiveness in Patients With Adamantinomatous Craniopharyngioma. Front Neurol. 2021; 12:704130. PMC: 8710480. DOI: 10.3389/fneur.2021.704130. View

Wesley U, Sutton I, Clark P, Cunningham K, Larrain C, Kuo J . Enhanced expression of pentraxin-3 in glioblastoma cells correlates with increased invasion and IL8-VEGF signaling axis. Brain Res. 2021; 1776:147752. DOI: 10.1016/j.brainres.2021.147752. View

Samstein R, Lee C, Shoushtari A, Hellmann M, Shen R, Janjigian Y . Tumor mutational load predicts survival after immunotherapy across multiple cancer types. Nat Genet. 2019; 51(2):202-206. PMC: 6365097. DOI: 10.1038/s41588-018-0312-8. View

Gromeier M, Brown M, Zhang G, Lin X, Chen Y, Wei Z . Very low mutation burden is a feature of inflamed recurrent glioblastomas responsive to cancer immunotherapy. Nat Commun. 2021; 12(1):352. PMC: 7806846. DOI: 10.1038/s41467-020-20469-6. View

Li H, Anton van der Merwe P, Sivakumar S . Biomarkers of response to PD-1 pathway blockade. Br J Cancer. 2022; 126(12):1663-1675. PMC: 9174485. DOI: 10.1038/s41416-022-01743-4. View

10.

Lee A, Sun L, Mochizuki A, Reynoso J, Orpilla J, Chow F . Neoadjuvant PD-1 blockade induces T cell and cDC1 activation but fails to overcome the immunosuppressive tumor associated macrophages in recurrent glioblastoma. Nat Commun. 2021; 12(1):6938. PMC: 8626557. DOI: 10.1038/s41467-021-26940-2. View

11.

Xiao B, Liu L, Li A, Xiang C, Wang P, Li H . Identification and Verification of Immune-Related Gene Prognostic Signature Based on ssGSEA for Osteosarcoma. Front Oncol. 2021; 10:607622. PMC: 7771722. DOI: 10.3389/fonc.2020.607622. View

12.

Schaettler M, Richters M, Wang A, Skidmore Z, Fisk B, Miller K . Characterization of the Genomic and Immunologic Diversity of Malignant Brain Tumors through Multisector Analysis. Cancer Discov. 2021; 12(1):154-171. PMC: 9296070. DOI: 10.1158/2159-8290.CD-21-0291. View

13.

Verdugo E, Puerto I, Medina M . An update on the molecular biology of glioblastoma, with clinical implications and progress in its treatment. Cancer Commun (Lond). 2022; 42(11):1083-1111. PMC: 9648390. DOI: 10.1002/cac2.12361. View

14.

Shen S, Guo J, Huang J, Zhang Q, Cui Y . Bromodomain-containing protein 4 activates cardiotrophin-like cytokine factor 1, an unfavorable prognostic biomarker, and promotes glioblastoma . Ann Transl Med. 2022; 10(8):475. PMC: 9096406. DOI: 10.21037/atm-22-1164. View

15.

Skiriute D, Vaitkiene P, Asmoniene V, Steponaitis G, Deltuva V, Tamasauskas A . Promoter methylation of AREG, HOXA11, hMLH1, NDRG2, NPTX2 and Tes genes in glioblastoma. J Neurooncol. 2013; 113(3):441-9. DOI: 10.1007/s11060-013-1133-3. View

16.

Sharma P, Aaroe A, Liang J, Puduvalli V . Tumor microenvironment in glioblastoma: Current and emerging concepts. Neurooncol Adv. 2023; 5(1):vdad009. PMC: 10034917. DOI: 10.1093/noajnl/vdad009. View

17.

Jelen S, Ulhoi B, Larsen A, Frokiaer J, Nielsen S, Rutzler M . AQP9 expression in glioblastoma multiforme tumors is limited to a small population of astrocytic cells and CD15(+)/CalB(+) leukocytes. PLoS One. 2013; 8(9):e75764. PMC: 3783410. DOI: 10.1371/journal.pone.0075764. View

18.

Weller M, Wick W, Aldape K, Brada M, Berger M, Pfister S . Glioma. Nat Rev Dis Primers. 2016; 1:15017. DOI: 10.1038/nrdp.2015.17. View

19.

Bader J, Voss K, Rathmell J . Targeting Metabolism to Improve the Tumor Microenvironment for Cancer Immunotherapy. Mol Cell. 2020; 78(6):1019-1033. PMC: 7339967. DOI: 10.1016/j.molcel.2020.05.034. View

20.

Steponaitis G, Kazlauskas A, Skiriute D, Vaitkiene P, Skauminas K, Tamasauskas A . Significance of Amphiregulin (AREG) for the Outcome of Low and High Grade Astrocytoma Patients. J Cancer. 2019; 10(6):1479-1488. PMC: 6485216. DOI: 10.7150/jca.29282. View